Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

Core Insights - Celldex Therapeutics, Inc. announced that an abstract detailing the 12-week results from its Phase 2 clinical trial of barzolvolimab for chronic spontaneous urticaria (CSU) has been accepted for presentation at the AAAAI Annual Meeting 2024 [1] - The trial aims to evaluate the efficacy and safety of barzolvolimab in patients with CSU who are resistant to antihistamines, with a total of 208 patients participating [2] Group 1 - The abstract titled "Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial" will be presented by Dr. Marcus Maurer on February 24, 2024 [1] - The study is a randomized, double-blind, placebo-controlled trial assessing multiple dosing regimens of barzolvolimab, with patients assigned to receive either 75 mg, 150 mg, 300 mg, or placebo [2] - The primary endpoint of the study is the mean change in Urticaria Activity Score over 7 days (UAS7) from baseline to Week 12, with secondary endpoints including other safety and clinical activity assessments [2] Group 2 - A webcast presentation of the data will be hosted by the company on February 25, 2024, at 9:45 AM ET, accessible via the Celldex Therapeutics website [3] - Celldex Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics that engage the human immune system to treat severe inflammatory, allergic, and autoimmune diseases [4]